8-K: Fortress Biotech Announces Second Quarter 2024 Financial Results and Corporate Updates

Fortress Biotech reported a 15% increase in product revenue compared to the previous quarter and provided updates on key regulatory milestones for its drug candidates.

Summary

• Fortress Biotech announced its financial results for the second quarter of 2024, highlighting a 15% increase in product revenue to $14.9 million compared to $13.0 million in the first quarter of 2024.
• The company's consolidated net revenue for the quarter was $14.9 million, down from $17.4 million in the same quarter of 2023.
• Consolidated research and development expenses decreased to $12.7 million from $32.1 million in the second quarter of 2023.
• The net loss attributable to common stockholders was $(13.3) million, or $(0.73) per share, compared to a net loss of $(26.9) million, or $(3.65) per share, in the second quarter of 2023.
• Fortress had $76.2 million in cash and cash equivalents as of June 30, 2024, a decrease from $83.8 million at the end of the previous quarter.
• The company has two key drug candidates with PDUFA goal dates in the fourth quarter of 2024: DFD-29 for rosacea (November 4, 2024) and cosibelimab for metastatic or locally advanced cutaneous squamous cell carcinoma (December 28, 2024).
• A potential fourth BLA submission is anticipated as early as 2025.
• The company paused dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock to maintain financial flexibility, deferring approximately $0.7 million in monthly cash dividend payments.
• Fortress reduced its total debt by $15 million by entering into a new loan agreement with Oaktree Capital Management.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive developments like increased product revenue and debt reduction, the overall financial results show a net loss and a decrease in cash, and the pausing of dividends is a negative signal. The company has key regulatory milestones ahead, which could shift the sentiment.

Positives

• Product revenue saw a significant increase of 15% compared to the previous quarter.
• Two key drug candidates, DFD-29 and cosibelimab, have PDUFA goal dates in the fourth quarter of 2024, indicating potential near-term regulatory approvals.
• The company has reduced its debt by $15 million, improving its financial position.
• Research and development expenses have decreased significantly year-over-year, indicating improved cost management.
• The net loss per share has improved from $(3.65) to $(0.73) year-over-year.

Negatives

• Consolidated net revenue decreased from $17.4 million in Q2 2023 to $14.9 million in Q2 2024.
• The company experienced a net loss of $(13.3) million for the quarter.
• Cash and cash equivalents decreased by $7.6 million during the quarter.
• The company has paused dividends on its Series A Preferred Stock, which may be concerning for some investors.

Risks

• The company's growth strategy relies on successful acquisitions and development of product candidates, which are subject to regulatory and clinical risks.
• The company needs substantial additional funds and is subject to uncertainties relating to financings.
• There are risks associated with the early stage of products under development and the results of research and development activities.
• The company faces risks related to obtaining regulatory approval for products under development and successfully commercializing them.
• The company is subject to government regulation, patent and intellectual property matters, and competition.

Future Outlook

Fortress anticipates an exciting second half of the year with two key drug candidates having PDUFA goal dates in the fourth quarter of 2024 and a potential fourth BLA submission as early as 2025. The company aims to expand its business and revenue streams for long-term success.

Management Comments

• Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, said, 'We had a very productive first half of the year and we anticipate an exciting second half, as we have a New Drug Application (NDA) and a Biologics License Application (BLA) on file with the U.S. Food and Drug Administration (FDA) from our diversified portfolio, both with PDUFA goal dates in the fourth quarter, including DFD-29 for rosacea and cosibelimab for metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).'
• Management stated that the company continues to prioritize the development of its candidates and the expansion of its business for long-term success.
• Management believes pausing the dividend is in the best interest of the Company and its stakeholders to maintain financial flexibility ahead of potentially significant inflection points.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the biopharmaceutical industry, where companies like Fortress are focused on advancing drug candidates through regulatory pathways. The focus on dermatology and oncology aligns with areas of significant unmet medical need and market potential. The company's diversified approach, including partnerships and subsidiaries, is a common strategy in the industry to mitigate risk and maximize opportunities.

Comparison to Industry Standards

• Fortress's 15% increase in product revenue quarter-over-quarter is a positive sign, but the overall revenue decline year-over-year indicates potential challenges in commercialization or market dynamics. Companies like Journey Medical, which contributed to the revenue, are key to Fortress's performance.
• The decrease in R&D expenses is notable, but it's important to compare this to industry benchmarks for similar stage companies. Companies like Amgen or Regeneron, which have large R&D budgets, may have different strategies and timelines.
• The net loss of $(13.3) million is not uncommon for biopharmaceutical companies in the development phase, but it's crucial to monitor the trend and compare it to peers like BioMarin or Vertex, which have established revenue streams.
• The debt reduction of $15 million is a positive step, but the company's overall financial health needs to be assessed against industry standards for debt-to-equity ratios and cash burn rates. Companies like Gilead or AbbVie, which have strong cash positions, are good benchmarks.
• The PDUFA goal dates for DFD-29 and cosibelimab are critical milestones. The success of these approvals will be a key factor in Fortress's future performance. Comparing the timelines and success rates to other companies with similar drug candidates, such as those in the dermatology or oncology space, will be important.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the pausing of dividends on the Series A Preferred Stock.
• Employees may be impacted by the company's financial performance and strategic decisions.
• Customers may benefit from the potential approval of new treatments like DFD-29 and cosibelimab.
• Suppliers and creditors may be affected by the company's financial health and debt management.
• The company's partners and subsidiaries will be impacted by the company's overall performance and strategic direction.

Next Steps

• The company will focus on achieving regulatory approvals for DFD-29 and cosibelimab by their respective PDUFA goal dates.
• Topline data for the Phase 1b/2a clinical trial of AJ201 to treat SBMA are expected in the second half of 2024.
• Topline data for the Phase 2 clinical trial of Triplex for adults co-infected with HIV and CMV are anticipated in the fourth quarter of 2024.
• The company will continue to explore the combined therapeutic potential of cosibelimab with GC Cells Immuncell-LC.
• The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the suspension should be lifted.

Key Dates

Keywords

biopharmaceutical, drug development, regulatory approval, PDUFA, rosacea, cutaneous squamous cell carcinoma, DFD-29, cosibelimab, revenue, clinical trials, debt reduction, financial results